Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
MLTX logo MLTX
Upturn stock ratingUpturn stock rating
MLTX logo

MoonLake Immunotherapeutics (MLTX)

Upturn stock ratingUpturn stock rating
$51.18
Last Close (24-hour delay)
Profit since last BUY22.15%
upturn advisory
SELL
SELL since 1 day
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

09/17/2025: MLTX (1-star) is a SELL. SELL since 1 days. Simulated Profits (22.15%). Updated daily EoD!

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

16 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $76.36

1 Year Target Price $76.36

Analysts Price Target For last 52 week
$76.36 Target price
52w Low $31.42
Current$51.18
52w High $61.87

Analysis of Past Performance

Type Stock
Historic Profit 74.66%
Avg. Invested days 46
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 4.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 09/17/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 3.38B USD
Price to earnings Ratio -
1Y Target Price 76.36
Price to earnings Ratio -
1Y Target Price 76.36
Volume (30-day avg) 16
Beta 1.27
52 Weeks Range 31.42 - 61.87
Updated Date 09/17/2025
52 Weeks Range 31.42 - 61.87
Updated Date 09/17/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.79

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -24.99%
Return on Equity (TTM) -40.34%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 3032768670
Price to Sales(TTM) -
Enterprise Value 3032768670
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -41.53
Shares Outstanding 63501400
Shares Floating 24060046
Shares Outstanding 63501400
Shares Floating 24060046
Percent Insiders 15.41
Percent Institutions 94.84

ai summary icon Upturn AI SWOT

MoonLake Immunotherapeutics

stock logo

Company Overview

overview logo History and Background

MoonLake Immunotherapeutics was founded in 2021 and is focused on developing and commercializing innovative therapies for immune-mediated inflammatory diseases. The company licensed Sonelokimab from Merck KGaA in 2021 and went public in 2022.

business area logo Core Business Areas

  • Clinical Development: Focuses on the clinical development of Sonelokimab for various indications.
  • Research and Development: Discovery and development of novel therapies for immune-mediated inflammatory diseases.
  • Commercialization: Planning and execution of commercialization strategies for approved products.

leadership logo Leadership and Structure

Dr. Jorge Santos Da Silva is the Chief Executive Officer. The company has a board of directors and a management team focused on clinical development and commercialization.

Top Products and Market Share

overview logo Key Offerings

  • Sonelokimab: An investigational Nanobodyu00ae targeting IL-17A and IL-17F, under development for the treatment of hidradenitis suppurativa (HS), psoriasis, and psoriatic arthritis (PsA). It is still under clinical trials with no current market share or revenue. Competitors in this space include AbbVie (Humira, Skyrizi), Novartis (Cosentyx), and Eli Lilly (Taltz).

Market Dynamics

industry overview logo Industry Overview

The market for immune-mediated inflammatory disease therapies is large and growing, driven by increasing prevalence and unmet medical needs.

Positioning

MoonLake is positioned as a leader in IL-17A/F inhibition, targeting a broad range of inflammatory diseases. Its competitive advantage lies in Sonelokimab's potential best-in-class efficacy.

Total Addressable Market (TAM)

The TAM for IL-17 inhibitors in indications like HS, psoriasis, and PsA is estimated to be in the billions of dollars annually. MoonLake is positioned to capture a significant share of this market if Sonelokimab receives regulatory approval.

Upturn SWOT Analysis

Strengths

  • Novel IL-17A/F Nanobodyu00ae with potential for superior efficacy
  • Experienced management team
  • Strong clinical trial results (early stage)
  • Focused on large and growing market segments

Weaknesses

  • Single product focus (Sonelokimab)
  • No approved products and dependent on clinical trial success
  • Reliance on funding for clinical development
  • Relatively new company with limited commercial experience

Opportunities

  • Expansion of Sonelokimab into additional indications
  • Potential for partnerships and collaborations
  • Positive clinical trial results driving market value
  • Acquisition by a larger pharmaceutical company

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from established players
  • Patent challenges
  • Generic erosion post approval of new products

Competitors and Market Share

competitor logo Key Competitors

  • ABBV
  • NVS
  • LLY

Competitive Landscape

MoonLake faces competition from established pharmaceutical companies with marketed products for immune-mediated inflammatory diseases. Its competitive advantage hinges on the potential for Sonelokimab to offer superior efficacy and convenience.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is primarily reflected in increasing R&D spending and expansion of clinical programs.

Future Projections: Future growth is dependent on the successful development and commercialization of Sonelokimab. Analyst estimates vary based on clinical trial outcomes and market penetration assumptions.

Recent Initiatives: Advancement of Sonelokimab through Phase 2 and Phase 3 clinical trials, and exploration of new indications.

Summary

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company with a promising lead product candidate, Sonelokimab, targeting IL-17A/F. The company is financially stable and continues to develop its novel therapy for multiple indications. Successful clinical trials and regulatory approvals are essential for its growth; it faces intense competition from established players. A key risk is clinical trial failure, which would heavily impact its future.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • MoonLake Immunotherapeutics Investor Relations
  • Company SEC Filings
  • Analyst Reports
  • ClinicalTrials.gov

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on individual financial circumstances and after consulting with a qualified financial advisor. Market share data are estimates based on available information.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About MoonLake Immunotherapeutics

Exchange NASDAQ
Headquaters -
IPO Launch date 2020-10-20
Co-Founder, CEO & Director Dr. Jorge Santos da Silva Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 100
Full time employees 100

MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.